机译:脑转移患者的估算体黑素瘤患者的存活率:使用分子标记进行黑素瘤评分预后评估的更新(Melanoma-molgpa)
Minneapolis Radiat Oncol Minneapolis MN USA;
MD Anderson Canc Ctr Houston TX USA;
MD Anderson Canc Ctr Houston TX USA;
Univ Calif San Francisco San Francisco CA 94143 USA;
Univ Calif San Francisco San Francisco CA 94143 USA;
Minneapolis Radiat Oncol Minneapolis MN USA;
Massachusetts Gen Hosp Boston MA 02114 USA;
Univ Minnesota Biostat Minneapolis MN USA;
Univ Minnesota Biostat Minneapolis MN USA;
Mem Sloan Kettering Canc Ctr 1275 York Ave New York NY 10021 USA;
Mem Sloan Kettering Canc Ctr 1275 York Ave New York NY 10021 USA;
Univ Minnesota Minneapolis MN USA;
US Oncol Minneapolis MN USA;
Duke Univ Durham NC USA;
Duke Univ Durham NC USA;
Univ Colorado Denver CO 80202 USA;
Univ Colorado Denver CO 80202 USA;
Univ Maryland Baltimore MD 21201 USA;
Ctr Hosp Univ Montreal Montreal PQ Canada;
Ctr Hosp Univ Montreal Montreal PQ Canada;
Yale Univ New Haven CT USA;
Yale Univ New Haven CT USA;
Miami Canc Inst Miami FL USA;
机译:脑转移患者的估算体黑素瘤患者的存活率:使用分子标记进行黑素瘤评分预后评估的更新(Melanoma-molgpa)
机译:评估具有脑转移的肾细胞癌患者的生存:肾脏分级预后评估工具的更新
机译:累积的颅内肿瘤量增加了黑色素瘤脑转移患者存活的诊断特异性分级预后评估模型的预后价值
机译:2D和3D MRI纹理特征的辐射瘤评估,以分类肺癌和黑色素瘤的脑转移
机译:肾细胞癌患者转移和存活的预后因素分析
机译:使用分子标记(Melanoma-molGPA)进行黑色素瘤分级预后评估的验证
机译:用分子标记验证对黑色素瘤的分级预后评估(Melanoma-molgpa)